13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595855
Total reported value
$1.1B
$1.1B
41 檔
23.2%
During the Q2 2025 filing period, Opaleye Management Inc. (CIK: 0001595855) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.1B across 41 reported positions.
Opaleye Management Inc. executed strategic sector rebalancing during Q2 2025, establishing 5 new positions while fully exiting 9 holdings and trimming 12 positions.
In terms of portfolio concentration, the top 5 core holdings (including HROW, ETON, IMNM) accounted for 23.2% of total reported equity market value during Q2 2025.
Top New Position Initiated
SRPT
市值: $8.6M
Top Position Liquidated / Trimmed
PVLA
前期市值: $4.8M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HROW | Harrow Inc | Stock-Other | 24.13% | -3.92% | -1.26% | |
| 2 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 8.25% | +0.08% | +0.28% | |
| 3 | IMNM | Immunome Inc | Stock-Other | 6.64% | — | -0.58% | |
| 4 | SNWV | Sanuwave Health Inc | Stock-Other | 6.52% | -1.95% | +0.82% | |
| 5 | LQDA | Liquidia CORP | Stock-Other | 6.24% | +5.97% | +9.51% | |
| 6 | CDXS | Codexis Inc | Stock-Other | 6.22% | -0.07% | +32.63% | |
| 7 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 6.07% | -3.42% | -3.06% | |
| 8 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 3.90% | +0.32% | — | |
| 9 | OCUL | Ocular Therapeutix Inc | Stock-Other | 3.00% | -0.14% | — | |
| 10 | ARVN | Arvinas Inc | Stock-Other | 2.50% | — | -14.94% | |
| 11 | LRMR | Larimar Therapeutics Inc | Stock-Other | 2.40% | — | +114.72% | |
| 12 | IRON | Disc Medicine Inc | Stock-Other | 2.00% | +2.11% | +119.32% | |
| 13 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.73% | — | — | |
| 14 | VIGL | Vigil Neuroscience Inc | Stock-Other | 1.61% | — | — | |
| 15 | CGON | Cg Oncology Inc | Stock-Other | 1.40% | -0.74% | +62.21% | |
| 16 | XOMA | Xoma Royalty Corporation | Stock-Other | 1.30% | +0.06% | +0.81% | |
| 17 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.30% | -0.23% | +24.05% | |
| 18 | STOK | Stoke Therapeutics Inc | Stock-Other | 1.29% | -0.93% | +87.37% | |
| 19 | ANIK | Anika Therapeutics Inc | Stock-Other | 1.26% | — | +49.06% | |
| 20 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | Bond | 1.20% | — | — | |
| 21 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 1.17% | -0.28% | — | |
| 22 | DNA | Ginkgo Bioworks Holdings Inc | Stock-Other | 1.14% | — | -58.16% | |
| 23 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | Bond | 0.92% | — | — | |
| 24 | GOSS | Gossamer Bio Inc | Stock-Other | 0.88% | — | -17.32% | |
| 25 | RZLT | Rezolute Inc | Stock-Other | 0.82% | +0.44% | +94.29% | |
| 26 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.78% | +0.42% | — | |
| 27 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.76% | — | — | |
| 28 | CRGX | Cargo Therapeutics Inc | Stock-Other | 0.56% | — | — | |
| 29 | MBX | Mbx Biosciences Inc | Stock-Other | 0.55% | +0.28% | -4.27% | |
| 30 | ZYME | Zymeworks Inc | Stock-Other | 0.53% | — | +20.00% | |
| 31 | TARA | Protara Therapeutic Inc | Stock-Other | 0.52% | — | -50.58% | |
| 32 | ALMS | Alumis Inc | Stock-Other | 0.47% | -0.20% | — | |
| 33 | ZNTL | Zentalis Pharmaceuticals Inc | Stock-Other | 0.45% | +0.18% | -3.06% | |
| 34 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.43% | -0.02% | -50.94% | |
| 35 | RCEL | Avita Medical Inc | Stock-Other | 0.42% | — | -11.47% | |
| 36 | IRD | Opus Genetics Inc | Stock-Other | 0.23% | +0.12% | +3.83% | |
| 37 | DERM | Journey Medical CORP | Stock-Other | 0.14% | -0.37% | +37.04% | |
| 38 | ✓ | Elevation Oncology Inc | Stock-Other | 0.11% | — | — | |
| 39 | IBIO | Ibio Inc | Stock-Other | 0.06% | — | — | |
| 40 | PEPG | Pepgen Inc | Stock-Other | 0.05% | — | -42.86% | |
| 41 | ADGM | Adagio Medical Holdings Inc | Stock-Other | 0.03% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | SRPT | Sarepta Therapeutics Inc | +1.7% | NEW | New buy |
| 2 | VIGL | Vigil Neuroscience Inc | +1.6% | NEW | New buy |
| 3 | LRMR | Larimar Therapeutics Inc | +1.5% | +114.72% | Add |
| 4 | IMNM | Immunome Inc | +1.3% | -0.58% | Trim |
| 5 | IRON | Disc Medicine Inc | +1.1% | +119.32% | Add |
| 6 | STOK | Stoke Therapeutics Inc | +0.9% | +87.37% | Add |
| 7 | RVMD | Revolution Medicines Inc | +0.8% | NEW | New buy |
| 8 | HROW | Harrow Inc | +0.7% | -1.26% | Trim |
| 9 | CDXS | Codexis Inc | +0.5% | +32.63% | Add |
| 10 | RZLT | Rezolute Inc | +0.5% | +94.29% | Add |
| 11 | CGON | Cg Oncology Inc | +0.5% | +62.21% | Add |
| 12 | ALMS | Alumis Inc | +0.5% | NEW | New buy |
| 13 | OCUL | Ocular Therapeutix Inc | +0.4% | — | Unchanged |
| 14 | RYTM | Rhythm Pharmaceuticals Inc | +0.3% | -3.06% | Trim |
| 15 | XOMA | Xoma Royalty Corporation | +0.2% | +0.81% | Add |
| 16 | MBX | Mbx Biosciences Inc | +0.1% | -4.27% | Trim |
| 17 | ✓ | Elevation Oncology Inc | +0.1% | NEW | New buy |
| 18 | ZYME | Zymeworks Inc | +0.1% | +20.00% | Add |
| 19 | DERM | Journey Medical CORP | +0.1% | +37.04% | Add |
| 20 | PTGX | Protagonist Therapeutics Inc | 0% | — | Unchanged |
| 21 | ETON | Eton Pharmaceuticals Inc | 0% | +0.28% | Add |
| 22 | ADGM | Adagio Medical Holdings Inc | 0% | — | Unchanged |
| 23 | EPIEUR | Essa Pharma Inc | 0% | — | Unchanged |
| 24 | CRGX | Cargo Therapeutics Inc | 0% | — | Unchanged |
| 25 | VTYXUSD | Ventyx Biosciences Inc | -0.1% | EXIT | Sold out |
| 26 | ANIK | Anika Therapeutics Inc | -0.1% | +49.06% | Add |
| 27 | PEPG | Pepgen Inc | -0.1% | -42.86% | Trim |
| 28 | KPTI 3 10-15-25Bond | Karyopharm Therapeutics | -0.1% | — | Unchanged |
| 29 | IRD | Opus Genetics Inc | -0.1% | +3.83% | Add |
| 30 | SGMOQ | Sangamo Therapeutics Inc | -0.2% | EXIT | Sold out |
| 31 | GOSS | Gossamer Bio Inc | -0.2% | -17.32% | Trim |
| 32 | GOSS 5 06-01-27Bond | Gossamer Bio Inc | -0.2% | — | Unchanged |
| 33 | ZNTL | Zentalis Pharmaceuticals Inc | -0.3% | -3.06% | Trim |
| 34 | IBIO | Ibio Inc | -0.3% | — | Unchanged |
| 35 | NRIX | Nurix Therapeutics Inc | -0.3% | EXIT | Sold out |
| 36 | KNSA | Kiniksa Pharmaceuticals International, plc | -0.3% | EXIT | Sold out |
| 37 | RCEL | Avita Medical Inc | -0.4% | -11.47% | Trim |
| 38 | DNA | Ginkgo Bioworks Holdings Inc | -0.4% | -58.16% | Trim |
| 39 | OPTNUSD | Optinose Inc | -0.4% | EXIT | Sold out |
| 40 | ✓ | Biodesix Inc | -0.5% | EXIT | Sold out |
| 41 | ARVN | Arvinas Inc | -0.6% | -14.94% | Trim |
| 42 | EWTX | Edgewise Therapeutics Inc | -0.6% | +24.05% | Add |
| 43 | TRVI | Trevi Therapeutics Inc | -0.7% | -50.94% | Trim |
| 44 | TGTX | Tg Therapeutics Inc | -0.8% | — | Unchanged |
| 45 | ✓ | Acelyrin Inc | -0.9% | EXIT | Sold out |
| 46 | ANAB | Anaptysbio Inc | -1% | EXIT | Sold out |
| 47 | PVLA | Palvella Therapeutics Inc | -1.1% | EXIT | Sold out |
| 48 | TARA | Protara Therapeutic Inc | -1.1% | -50.58% | Trim |
| 49 | SNWV | Sanuwave Health Inc | -1.1% | +0.82% | Add |
| 50 | LQDA | Liquidia CORP | -1.2% | +9.51% | Add |
According to official SEC Form 13F filings, Opaleye Management Inc. reported a total U.S. public equity portfolio value of $1.1B across 41 disclosed positions in Q2 2025.
During Q2 2025, Opaleye Management Inc.'s top holdings by market value included HROW (24.1%)、ETON (8.3%)、IMNM (6.6%). The largest single position, HROW, represented 24.1% of total portfolio value.
In Q2 2025, Opaleye Management Inc. made 41 total portfolio adjustments, initiating 5 new buys, adding to 15 positions, trimming 12 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.